By contrast, despite the widespread use of SMO inhibitors, the value of SMO as a prognostic biomarker is less profound and has only been reported in a handful of cancer types, including bladder cancer [222], glioma [223,224], liver cancer [68], and head-and-neck cancer [209]. This evidence concerns the gene SMO and urinary bladder carcinoma.